Nurix Therapeutics Inc (NRIX) Stock Price, Quote & News

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK)...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 660 5320

Fax: 415-525-4200

Website: www.nurixtx.com

Address:

1600 Sierra Point Parkway, Brisbane, United States

oaksapollo Apr. 24 at 7:11 PM

$NRIX new deck on my FAVORITE Nurix molecule: https://www.nurixtx.com/wp-content/uploads/2026/04/AACR-2026-%E2%80%94-CBL-B-Glue-Inhibitors-Presentation.pdf I think 1607+anti-PD1 will be one of the most effective cancer treatments (across tumor types) that we've ever seen.

0 · Reply

oaksapollo Apr. 23 at 4:57 PM

$NRIX In this biotech environment, I don't understand how no one has bought Nurix. I'm not saying I want it to happen, but if Lilly is willing to pay up to $7B for Kelonia, how in the hell is no one chasing Nurix for their degrader platform (and robust pipeline) which is currently valued at <$2B (a steal!) IMO degraders are the next revolution in medicine. We started with small molecules, then biologics (primarily MAbs), cell therapy like CAR T, and now degraders are next. If Nurix is still an independent company at YE, I will be very surprised

2 · Reply

oaksapollo Apr. 22 at 4:28 PM

$NRIX Some new data posted https://www.nurixtx.com/resource-library/

0 · Reply

LongTrainRunning Apr. 22 at 1:30 PM

$NRIX EHA is just 7 weeks away. Let's hear your price predictions. I'm hoping we'll see $20 just before EHA and then $25 when we get new data.

1 · Reply

Biotech_Pharma_Investor Apr. 21 at 7:41 AM

$PRLD next catalyst will be DAC partnership. Even though pipeline is early each asset has best-in-class potential in large TAMs RA funding (following Incyte partnership) further validates the potential. Recent expansion of $CCCC partnership with Roche also validates DAC interest. Not many public small/mid-cap DAC players $PRLD $CCCC $NRIX $GYRE (other?)

1 · Reply

Doozio Apr. 19 at 5:11 PM

$NRIX chop chop huckleberries… ONTO 🐒🍌🧠⏰♾️

0 · Reply

Wigglyick Apr. 17 at 4:40 PM

$NRIX NURIX THERAPEUTICS

0 · Reply

LongTrainRunning Apr. 13 at 5:04 PM

$NRIX I bought some $20 July calls for $2 today. Maybe that's a stretch but EHA is 8 weeks and I'm betting that the run up alone will double the price of the calls - and that's before we get any data. Good luck longs!

0 · Reply

PenkeInvesting Apr. 12 at 6:03 PM

Fundamental analysis of $NRIX (Nurix Therapeutics, Inc.) based on financial data and reported results. #NRIX #Nurix

0 · Reply

oaksapollo Apr. 4 at 12:34 AM

$NRIX new slide deck https://www.nurixtx.com/wp-content/uploads/2026/04/Nurixs-Unique-Approach-to-DAC-Discovery_ACS-2026-03.pdf This slide is pretty interesting; same target but different antibodies giving you VERY different results.

0 · Reply

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Apr 13, 2026, 1:30 PM EDT - 12 days ago

Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 6:00 AM EDT - 17 days ago

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Apr 7, 2026, 7:00 AM EDT - 18 days ago

Nurix Therapeutics to Participate in Upcoming Investor Conference

Mar 23, 2026, 4:05 PM EDT - 4 weeks ago

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

Feb 12, 2026, 12:00 PM EST - 2 months ago

Nurix Therapeutics Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Jan 28, 2026, 4:01 PM EST - 3 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

Jan 12, 2026, 7:30 PM EST - 3 months ago

Nurix Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 3 months ago

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Jan 5, 2026, 7:00 AM EST - 3 months ago

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 8, 2025, 8:15 PM EST - 4 months ago

Nurix Therapeutics Transcript: Study Update

Dec 8, 2025, 8:00 AM EST - 4 months ago

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

$Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition$

Dec 6, 2025, 9:30 AM EST - 5 months ago

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Dec 3, 2025, 12:30 PM EST - 5 months ago

Nurix Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 5 months ago

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 25, 2025, 7:00 AM EST - 5 months ago

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 6:00 AM EST - 5 months ago

Nurix Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 9:20 AM EST - 5 months ago

Nurix Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 7:00 AM EST - 5 months ago

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nov 7, 2025, 9:00 AM EST - 6 months ago

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nov 3, 2025, 9:00 AM EST - 6 months ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Oct 27, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Nurix Therapeutics Transcript: Study Update

Oct 22, 2025, 7:20 AM EDT - 6 months ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

$Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia$

Oct 22, 2025, 6:00 AM EDT - 6 months ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Oct 18, 2025, 3:00 AM EDT - 6 months ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Oct 9, 2025, 4:01 PM EDT - 7 months ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Sep 17, 2025, 7:00 AM EDT - 7 months ago

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Sep 16, 2025, 11:00 AM EDT - 7 months ago

Nurix Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 10, 2025, 7:00 AM EDT - 8 months ago

Nurix Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 10:50 AM EDT - 8 months ago

Nurix Therapeutics Transcript: Baird Global Healthcare Conference 2025

Sep 8, 2025, 1:30 PM EDT - 8 months ago

Nurix Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 1:30 PM EDT - 8 months ago

Nurix Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Jul 9, 2025, 4:01 PM EDT - 10 months ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 7, 2025, 7:00 AM EDT - 10 months ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jun 13, 2025, 4:01 PM EDT - 11 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2025, 8:00 AM EDT - 11 months ago

Nurix Therapeutics Transcript: Study Update

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$

Jun 12, 2025, 7:00 AM EDT - 11 months ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 6, 2025, 7:00 AM EDT - 11 months ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 4, 2025, 3:45 PM EDT - 11 months ago

Nurix Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 7:00 AM EDT - 11 months ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

May 28, 2025, 7:00 AM EDT - 11 months ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 21, 2025, 2:05 PM EDT - 1 year ago

Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:30 AM EDT - 1 year ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Apr 28, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 8, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 13, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Nurix Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Feb 11, 2025, 12:40 PM EST - 1 year ago

Nurix Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 4:00 PM EST - 1 year ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 22, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Jan 13, 2025, 6:00 PM EST - 1 year ago

Nurix Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

$Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia$

Dec 19, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Dec 9, 2024, 11:15 PM EST - 1 year ago

Nurix Therapeutics Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Dec 9, 2024, 6:00 PM EST - 1 year ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Dec 3, 2024, 2:30 PM EST - 1 year ago

Nurix Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nov 25, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 6:30 AM EST - 1 year ago

Nurix Therapeutics Transcript: Jefferies London Healthcare Conference 2024

$Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia$

Nov 20, 2024, 4:00 PM EST - 1 year ago

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nov 18, 2024, 4:45 PM EST - 1 year ago

Nurix Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 17, 2024, 10:30 AM EST - 1 year ago

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nov 12, 2024, 8:00 PM EST - 1 year ago

Nurix Therapeutics Transcript: UBS Global Healthcare Conference 2024

Oct 21, 2024, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

$Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia$

Oct 19, 2024, 8:00 AM EDT - 1 year ago

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Sep 9, 2024, 9:30 AM EDT - 1 year ago

Nurix Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Nurix Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Jul 15, 2024, 2:30 PM EDT - 1 year ago

Nurix Therapeutics Transcript: UBS Targeted Protein Degradation Day 2024

Jun 16, 2024, 9:00 AM EDT - 2 years ago

Nurix Therapeutics Transcript: Study Update

Jun 5, 2024, 5:30 PM EDT - 2 years ago

Nurix Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 14, 2024, 9:30 AM EDT - 2 years ago

Nurix Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

Apr 16, 2024, 1:00 PM EDT - 2 years ago

Nurix Therapeutics Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 8, 2024, 11:00 AM EDT - 2 years ago

Nurix Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Jan 8, 2024, 6:00 PM EST - 2 years ago

Nurix Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Dec 11, 2023, 8:30 AM EST - 2 years ago

Nurix Therapeutics Transcript: ASH 2023

Nov 29, 2023, 3:00 PM EST - 2 years ago

Nurix Therapeutics Transcript: The Piper Sandler 35th Annual Healthcare Conference

Sep 12, 2023, 12:15 PM EDT - 2 years ago

Nurix Therapeutics Transcript: Baird's Global Healthcare Conference 2023

Sep 7, 2023, 8:30 AM EDT - 2 years ago

Nurix Therapeutics Transcript: Collaboration

oaksapollo Apr. 24 at 7:11 PM

0 · Reply

oaksapollo Apr. 23 at 4:57 PM

2 · Reply

oaksapollo Apr. 22 at 4:28 PM

$NRIX Some new data posted https://www.nurixtx.com/resource-library/

0 · Reply

LongTrainRunning Apr. 22 at 1:30 PM

$NRIX EHA is just 7 weeks away. Let's hear your price predictions. I'm hoping we'll see $20 just before EHA and then $25 when we get new data.

1 · Reply

Biotech_Pharma_Investor Apr. 21 at 7:41 AM

1 · Reply

Doozio Apr. 19 at 5:11 PM

$NRIX chop chop huckleberries… ONTO 🐒🍌🧠⏰♾️

0 · Reply

Wigglyick Apr. 17 at 4:40 PM

$NRIX NURIX THERAPEUTICS

0 · Reply

LongTrainRunning Apr. 13 at 5:04 PM

0 · Reply

PenkeInvesting Apr. 12 at 6:03 PM

Fundamental analysis of $NRIX (Nurix Therapeutics, Inc.) based on financial data and reported results. #NRIX #Nurix

0 · Reply

oaksapollo Apr. 4 at 12:34 AM

0 · Reply

oaksapollo Mar. 27 at 11:36 AM

$NRIX Just a bit of competition. I have looked at all of these, and Nurix is the only one I find compelling from both a scientific and investment perspective. Anyone else have a different favorite?

2 · Reply

OfficialStocktwitsUser Mar. 27 at 2:58 AM

$NRIX RSI: 54.43, MACD: -0.3470 Vol: 0.51, MA20: 15.38, MA50: 16.40 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

stjernerogvann Mar. 11 at 5:52 PM

$SLS by comparison, $NRIX has a $1.6B market cap, is only in P2, and is going after a similarly sized leukemia indication (CLL.) $SLS is farther along and seems to have objective evidence that GPS works so it should be at least 1.5x $NRIX market cap, IMO.

1 · Reply

LongTrainRunning Mar. 6 at 7:41 PM

$NRIX This could be our last chance to load up at these prices before EHA. Once the weak sellers exit and volume picks up things will look brighter.

0 · Reply

LongTrainRunning Mar. 4 at 7:42 PM

$NRIX it's been a gradual decline since ASH in December, which isn't a big surprise. But EHA is quickly approaching in June. We're basically at the halfway point and we should start to see a meaningful run up in the next month or two. I'm betting that EHA will give us more positive data that are 6 months more mature than ASH 2025. I'm hoping that we revisit the highs we saw in December before we even see new data. Good luck longs!

0 · Reply

oaksapollo Mar. 3 at 2:12 AM

$NRIX You guys see the Roche fenebrutinib data in MS? If a BTK inhibitor works that well, a BTK degrader could be a game changer in MS.

1 · Reply

oaksapollo Feb. 24 at 3:41 AM

$NRIX Gilead was probably the most logical acquirer of Nurix. Seems impossible now, at least in the near term, due to their $8B buy of Arcellx. Guess we have to play the long game now.

1 · Reply

OfficialStocktwitsUser Feb. 22 at 6:31 PM

$NRIX RSI: 41.55, MACD: -0.6694 Vol: 1.14, MA20: 16.76, MA50: 18.00 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

oaksapollo Feb. 18 at 3:12 AM

$NRIX nice to see Baker Bros continue to increase their position

2 · Reply

oaksapollo Feb. 16 at 5:02 PM

$NRIX What do you guys think is the likelihood of Nurix being acquired? Seems like it would be an absolutely perfect strategic fit for Gilead. I feel like if anyone were going to do it, now would be the time - bexo has been significantly de-risked, but an approved product is still a few years away so market cap is quite reasonable.

1 · Reply

LongTrainRunning Feb. 12 at 9:50 PM

$NRIX bought some more today. Hopefully we'll level out soon. March is the midpoint between ASH 2025 and EHA 2026. So it might keep drifting down until the run-up begins in April or May. Tremendous value right now.

1 · Reply

Market Cap	1.71B
Revenue (ttm)	83.98M
Net Income (ttm)	-264.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-314.91%
Debt to Equity Ratio	0.00

Volume	575,600
Avg Vol	1,117,476
Day's Range	N/A - N/A
Shares Out	103.41M
Stochastic %K	42%
Beta	1.97
Analysts	Strong Sell
Price Target	$30.18